Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Safety and Feasibility Trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

NCT02728700 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02728700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Safety and Feasibility Trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Terminated
Start date
February 29, 2016
Completion date
July 31, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult hodgkin lymphoma, adult myelodysplastic syndrome, blast phase chronic myelogenous leukemia, bcr-abl1 positive, childhood chronic myelogenous leukemia, bcr-abl1 positive, childhood hodgkin lymphoma, childhood myelodysplastic syndrome, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, myelofibrosis, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent adult non-hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood non-hodgkin lymphoma, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory non-hodgkin lymphoma